BioCentury | Jun 26, 2020
Finance
June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more
...during ex vivo CAR T processing and engineering. E round to fuel Enterome trial starts Enterome Bioscience S.A....
...NASDAQ:EVLO), $45 million. Targets Cbl-b - Casitas B cell lymphoma-b BioCentury Staff Nurix Therapeutics Inc. Hutchison China MediTech Ltd. Enterome Bioscience S.A. NantKwest...
...NASDAQ:EVLO), $45 million. Targets Cbl-b - Casitas B cell lymphoma-b BioCentury Staff Nurix Therapeutics Inc. Hutchison China MediTech Ltd. Enterome Bioscience S.A. NantKwest...